Karachi December 15 2023: The Searle Company Limited has received approval from the Drug Regulatory Authority of Pakistan (DRAP) for ADALIMUMAB, a biosimilar drug developed in collaboration with BioRay Biopharmaceuticals Co. Limited, China.
This marks the first locally manufactured Monoclonal antibody (mABs) in Pakistan.
The introduction of ADALIMUMAB to the market within the next 3-6 months is a strategic move aimed at providing high-quality, affordable biotechnology medicines to patients in Pakistan. This development aligns with our commitment to diversifying our product portfolio, thereby enhancing the quality of earnings and shareholders’ value.
